Results 21 to 30 of about 20,131,715 (394)

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

Vaccines, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production.
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Rui Costa, Nandini Prabhakar Venkatesan, Xiangliang Lin, Long Van Pham, Shan Feng, Ulrik Fahnøe, Troels Kasper Høyer Scheel, Santseharay Ramirez, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein   +14 more
doaj   +1 more source

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Viruses, 2023
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development.
Karen Anbro Gammeltoft, Yuyong Zhou, Line Abildgaard Ryberg, Long V. Pham, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard, Ulrik Fahnøe, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein   +11 more
doaj   +1 more source

[Hepatitis C]. [PDF]

La Clinica terapeutica, 1996
HCV carriers are supposed to me 100,000,000 worldwide. 5-15% of subjects are infected via haemotransfusion and another significant amount via intravenous drugs; nevertheless in the major part of subjects the via of transmission remains unclear. HCV causes long-term infectious in the host because of its high frequency of mutations.
GATTONI A, CECERE A, CAIAZZO R, ROMANO, Ciro Pasquale   +3 more
  +8 more sources

Chronic hepatitis C elimination prison initiative: HCV‐intensive test and treat, a whole prisoner population HCV test‐and‐treat program in England

Health Science Reports, 2023
Background and Aim Prison residents are at high risk for hepatitis C virus (HCV) infection. HCV test‐and‐treat initiatives within prisons provide an opportunity to engage with prison residents and achieve HCV micro‐elimination.
Rachel Halford, Lee Christensen, Sean Cox, Julia Sheehan, Iain Brew, Mark Gillyon‐Powell, Georgia Threadgold, Éamonn O'Moore, Philip J. F. Troke, Andy Jones   +9 more
doaj   +1 more source

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

Viruses, 2021
We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Yuyong Zhou, Karen A. Gammeltoft, Andrea Galli, Anna Offersgaard, Ulrik Fahnøe, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein   +7 more
doaj   +1 more source

Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro

Proceedings, 2020
Epitope shielding is suggested as an important mechanism mediating the escape of hepatitis C virus (HCV) from host-neutralizing antibodies (nAb). [...]
Garazi Peña Alzua, Anne Finne Pihl, Anna Falden Offersgaard, Rodrigo Velázquez-Moctezuma, Elias Honeroed Augestad, Ulrik Fahnøe, Christian Kjaerulff Mathiesen, Mansun Law, Jannick Prentoe, Jens Bukh, Judith Margarete Gottwein   +10 more
doaj   +1 more source

CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020

MMWR Recommendations and Reports, 2020
Summary Hepatitis C virus (HCV) infection is a major source of morbidity and mortality in the United States. HCV is transmitted primarily through parenteral exposures to infectious blood or body fluids that contain blood, most commonly through injection ...
R. Redfield, Maureen A. Leahy, Julia C. Martinroe, Stephen R. Spriggs, Tong Yang, S. Schillie, Carolyn Wester, L. Wesolowski   +7 more
semanticscholar   +1 more source

Screening and Treatment Program to Eliminate Hepatitis C in Egypt.

New England Journal of Medicine, 2020
Screening Program to Eliminate Hepatitis C in Egypt In 2018, the Egyptian government initiated a massive hepatitis C screening and treatment program.
I. Waked, G. Esmat, A. Elsharkawy, M. El-Serafy, W. Abdel-Razek, Reham Ghalab, G. Elshishiney, Aysam Salah, Soad Abdel Megid, K. Kabil, M. El-Sayed, H. Dabbous, Y. El Shazly, Mohamed Abo Sliman, Khalid Abou Hashem, Sayed Abdel Gawad, Nevine M. El Nahas, Ahmed El Sobky, Sahar El Sonbaty, Hamdy El Tabakh, E. Emad, Hany Gemeah, A. Hashem, M. Hassany, N. Hefnawy, Abdel N Hemida, Ayman Khadary, Kamal B. Labib, Faisal Mahmoud, Said Mamoun, T. Marei, S. Mekky, A. Meshref, Alaa Othman, O. Ragab, E. Ramadan, A. Rehan, T. Saad, R. Saeed, M. Sharshar, H. Shawky, M. Shawky, W. Shehata, Hanaa Soror, Mohsen Taha, M. Talha, Adel Tealaab, M. Zein, Alaa Hashish, A. Cordie, Y. Omar, Ehab Kamal, I. Ammar, Mohamed Abdalla, Wafaa El Akel, W. Doss, H. Zaid   +56 more
semanticscholar   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe, Dickson, Adele, Flowers, Paul, Hayes, Peter, Krzeczkowska, Anna   +4 more
core   +3 more sources

Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis

BMC Cancer, 2019
Background Hepatocellular carcinoma (HCC) is the sixth-most common malignancy worldwide. Multiple previous studies have assessed the relationship between TM6SF2 gene polymorphism and the risk of developing HCC, with discrepant conclusions reached.
Shan Tang, Jing Zhang, Ting-Ting Mei, Hai-Qing Guo, Xin-Huan Wei, Wen-Yan Zhang, Ya-Li Liu, Shan Liang, Zuo-Peng Fan, Li-Xia Ma, Wei Lin, Yi-Rong Liu, Li-Xia Qiu, Hai-Bin Yu   +13 more
doaj   +1 more source